Lenalidomide treatment promotes CD 154 expression on CLL cells and enhances production of antibodies by normal B cells through a P13-kinase-dependent pathwayLAPALOMBELLA, Rosa; ANDRITSOS, Leslie; SMITH, Lisa L et al.Blood. 2010, Vol 115, Num 13, pp 2619-2629, issn 0006-4971, 11 p.Article

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemiaHERMAN, Sarah E. M; LAPALOMBELLA, Rosa; BYRD, John C et al.Blood. 2011, Vol 117, Num 16, pp 4323-4327, issn 0006-4971, 5 p.Article

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. CommentaryKAY, Neil E; LAPALOMBELLA, Rosa; ANDRITSOS, Leslie et al.Blood. 2008, Vol 112, Num 13, issn 0006-4971, 4785-4786, 5180-5189 [12 p.]Article

Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemiaBO YU; YICHENG MAO; JARJOURA, David et al.Blood. 2013, Vol 121, Num 1, pp 136-147, issn 0006-4971, 12 p.Article

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765HERMAN, Sarah E. M; GORDON, Amber L; HAMDY, Ahmed et al.Blood. 2011, Vol 117, Num 23, pp 6287-6296, issn 0006-4971, 10 p.Article

IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. CommentaryKOLB, Jean-Pierre; GOWDA, Aruna; CARSON, William E et al.Blood. 2008, Vol 111, Num 9, issn 0006-4971, 4424-4425, 4723-4730 [10 p.]Article